Superworth

Alector price to book ratio ALEC

Market value divided by the book value of the company's net assets, since 2019.

Today, Nov 2, 2026
n/m
not a meaningful number
Last meaningful
16.1×
Jul 2026
7-year median
3.6×
7-year range
0.7× to 23.6×
Peer median
4.2×

Alector's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Jul 2026, at 16.1×.

On the days it had one over the last 7 years, its median was 3.6×, from 0.7× in Apr 2025 to 23.6× in May 2026.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far16.1×2.9×23.6×
20252.7×0.7×4.7×
20241.5×1.5×5.3×
20234.1×2.2×4.3×
20223.0×2.4×4.4×
20215.0×3.9×12.9×
20203.9×2.1×11.1×
20195.5×4.0×6.4×

Against its peers

Companies in Biotechnology nearest Alector's size, closest first, today.

CompanyPrice to book ratio
ALECAlectorn/m
PLXProtalix BioTherapeutics2.9×
MGTXMeiraGTx4.2×
VCELVericel5.6×
Peer median4.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Alector

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.